Blazejewski MEDI-TECH GmbH is one of the technology leaders in the field of complex 2D and 3D endoscopy and has been able to grow very strongly in recent years Reinhold Blazejewski, Founder and Managing Director of Blazejewski MEDI-TECH, also sells part of his shares to the Erbe Group, but remains with the company as a […]
Tübingen / 18.08.2022 Manfred Ulmer-Weber has been appointed to the management board of SHS Gesellschaft für Beteiligungsmanagement mbH. Ulmer-Weber will be jointly responsible for the allocation of the new SHS VI fund of the Tübingen-based sector specialist. The additional Managing Partner is an SHS home-grown and started his career at SHS in 2010. The shareholders […]
SHS Gesellschaft für Beteiligungsmanagement has received capital commitments of over 220 million euros for its sixth fund at the first closing. Faster than expected, the Tübingen-based healthcare investor has already exceeded its target of 200 million euros at the first closing. The sixth SHS fund generation also aims at majority and minority investments in the […]
Before joining SHS, Lukas worked as a manager at one of the Big Four auditing firms in southern Germany. He completed his Bachelor of Science in Business Administration with a focus on Corporate Accounting and Finance at the LMU in Munich. He completed his Master’s degree at the University of Mannheim with a focus on […]
The fast-growing Norwegian healthcare provider Dropin enables short-term medical consultation and treatment – in person on site as well as digitally via app Dropin posted revenue of more than 30m EUR in 2021, constituting a CAGR of more than 100% for the last three years SHS invests from its fifth fund generation in the Scandinavian […]
The fast-growing MedTech company phenox specialises in instruments and implants for the neurointerventional therapy of stroke With the growth capital provided by SHS et al., the Bochum-based company has developed from a start-up into a global leader in the field of stroke therapy A successful exit for investors from the third SHS fund generation The […]
c-LEcta was able to translate technology leadership into tremendous commercial growth during the holding period of SHS Leipzig-based c-LEcta’s clients include international corporations in the pharmaceutical, chemical and food industries. With the acquisition, Kerry Group intends to further expand the internationalization of the company in the field of enzymes Tübingen / 15.02.2022 The Tübingen-based growth […]
VAMDRUP, Denmark, February 3rd, 2022 – Impilo and SHS have acquired Lowenco A/S (“Lowenco” or the “Company”) from its founder and owners. Lowenco was founded 2013 in Vamdrup, Denmark, and develops, manufactures, markets, and installs large scale modular and highly energy efficient ultra-low temperature (“ULT”) storage solutions for commercial biopharma, primarily targeting the drug substance […]
Medical technology market in Germany to remain at a high level in 2020, but with slight declines Pandemic leaves both positive and negative traces on medical technology companies SHS expects better development for medical technology than for the overall economy in Germany in 2021 despite Corona The new regulatory requirements (MDR) continue to burden many […]
This funding round allocated in tranches will strengthen PathoQuest’s position as a leading NGS-based biosafety CRO for the biopharmaceutical industry. Paris, FRANCE, Tübingen, GERMANY – November 9th, 2021 – PathoQuest, a pioneer in the quality control of biologics using Next-Generation Sequencing (NGS), today announced the closing of a financing round up to €15M. This funding […]
SHS has been investing according to ethical standards for more than 25 years and its ESG policy is an important aspect of investment decisions. Now it is also becoming a member of the PRI (UN Principles for Responsible Investment) The Tübingen-based healthcare investor has committed itself to contractual compliance with the requirements of the UN […]
Atlas Antibodies acquires evitria Atlas Antibodies has agreed to acquire evitria, a world leader in transient recombinant antibody expression in CHO cells. This transformative acquisition brings together a leading provider of highly validated research antibodies and a front-runner in the field of custom recombinant antibody expression. Since its inception in 2010, evitria has been singularly […]
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information